Cargando…
IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) led to multiple drug repurposing clinical trials that have yielded largely uncertain outcomes. To overcome this challenge, we used IDentif.AI, a platform that pairs experimental validation with artificial intelligence (AI)...
Autores principales: | Blasiak, Agata, Lim, Jhin Jieh, Seah, Shirley Gek Kheng, Kee, Theodore, Remus, Alexandria, Chye, De Hoe, Wong, Pui San, Hooi, Lissa, Truong, Anh T. L., Le, Nguyen, Chan, Conrad E. Z., Desai, Rishi, Ding, Xianting, Hanson, Brendon J., Chow, Edward Kai‐Hua, Ho, Dean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823122/ https://www.ncbi.nlm.nih.gov/pubmed/33532594 http://dx.doi.org/10.1002/btm2.10196 |
Ejemplares similares
-
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens
por: Blasiak, Agata, et al.
Publicado: (2022) -
Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention
por: Abdulla, Aynur, et al.
Publicado: (2020) -
Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria
por: Mukherjee, Devika, et al.
Publicado: (2022) -
Genetic characterisation of influenza C viruses detected in Singapore in 2006
por: Ting, Pei‐jun, et al.
Publicado: (2015) -
Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
por: Lim, Jhin Jieh, et al.
Publicado: (2022)